Lung Cancer Trial Opened Door for New Research Opportunities

The recently completed trial on the immunotherapy drug pembrolizumab (Keytruda) at Sanford Health had important implications for non-small cell lung cancer patients in the region. Thanks to Sanford’s involvement, patients with an illness that is often fatal within a year, had access to a promising new treatment long before they might otherwise have even heard about it.